Abstracts Archive - Page 616 of 2607 - ACR Meeting Abstracts

Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 2005 • ACR Convergence 2022
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Toshihiro Matsui¹ and Shigeto Tohma², ¹NHO Sagamihara National Hospital, Kanagawa, Japan, ²National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: To clarify the current status and issues concerning treatment in the early stage of onset in patients with elderly-onset rheumatoid arthritis (RA) in Japan.Methods:…
Abstract Number: 1935 • ACR Convergence 2022
Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic
William Soulsby¹ and Emily von Scheven², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA
Background/Purpose: Racial disparities are prevalent in chronic illness, including pediatric rheumatic diseases. Prior work has investigated the impact of race on disease activity and damage…
Abstract Number: 1993 • ACR Convergence 2022
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
Esha Lal¹, Marta Sala Climent², francesca cedola², Marta Fernandez-Bustamante³, Meritxell Agustín-Perez², Maram Alharti², Abha Singh⁴, Soo-In Choi², Tania Rivera², Katherine Nguyen⁴, Susan Lee², Aaron Armando⁵, Tiffany Holt⁶, Oswald Quehenberger⁵, Shahrokh Golshan⁶, Roxana Coras⁷ and Monica Guma⁸, ¹Department of Medicine, School of Medicine, University of California, San Diego, San Diego, ²Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, ³Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, ⁴University of California, San Diego, San Diego, CA, ⁵Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, ⁶Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, ⁷University of California San Diego, San Diego, CA, ⁸UCSD, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Raphaèle Seror¹, Gabriel Baron², Sylvie Miconnet³, Rakiba Belkhir³, Martin Soubrier⁴, pascale thevenot⁵, andre basch⁶, Marie Truchetet⁷, Pascal Claudepierre⁸, Emmanuelle Dernis⁹, Hubert Marotte¹⁰, René-Marc Flipo¹¹, Olivier Brocq¹², Jacques Morel¹³, CARINE SALLIOT¹⁴, Bruno Fautrel¹⁵, Alain Saraux¹⁶, CHARLES LESKE¹⁷, Naïma Hamamouche¹⁸, Thierry schaeverbeke¹⁹, Xavier Mariette²⁰, Adeline Ruyssen-Witrand²¹ and Philippe Ravaud²², ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Gabriel-Montpied Hospital, Clermont-Ferrand, France, ⁵French Society of rheumatology, Paris, France, ⁶Infirmerie Protestante de Lyon, Caluire-et-Cuire, France, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸Paris Est Creteil University, Creteil, France, ⁹LE MANS general hospital, LE MANS, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹CHU Lille, Boulogne-Billancourt, France, ¹²Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹³University and CHU Montpellier, Montpellier, France, ¹⁴CHR orleans, Orleans, France, ¹⁵Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹⁶CHU Brest, Brest, France, ¹⁷Hospital, Cholet, France, ¹⁸e-health Services Sanoïa, Gémenos, France, ¹⁹CHU de Bordeaux, Bordeaux, France, ²⁰Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²¹CHU de Toulouse, Toulouse, France, ²²Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…
Abstract Number: 1997 • ACR Convergence 2022
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Renuka Nayak³, Anthony Jimenez Hernandez¹, Sydney Catron⁴, Zakwan Uddin⁴, Erin Reilly⁵, Andrew Patterson⁵, Peter Turnbaugh⁶, Jose Clemente² and Jose Scher⁷, ¹NYU School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴NYU Langone Health, New York, NY, ⁵Pennsylvania State University, College Park, PA, ⁶UCSF, San Francisco, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…
Abstract Number: 2008 • ACR Convergence 2022
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs
Alan Kivitz¹, Liangwei Wang², Ilias Alevizos², Michele Gunsior², Judith Falloon² and Gabor Illei³, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Horizon Therapeutics, Gaithersburg, MD, ³Horizon Therapeutics, Rockville, MD
Background/Purpose: Dazodalibep (DAZ), a non-antibody biologic antagonist of CD40L, led to higher/durable response rates vs. placebo (PBO) in a double-blind, Phase 1b trial of patients…
Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Malin Erlandsson¹, Karin Andersson¹, Sofia Töyrä Silfverswärd², Rille pullerits² and Maria Bokarewa², ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…
Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 2013 • ACR Convergence 2022
Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
Siri Lillegraven¹, Nina Paulshus Sundlisæter¹, Anna-Birgitte Aga¹, Joe Sexton¹, Inge Christoffer Olsen², Hallvard Fremstad³, Cristina Spada⁴, Tor Magne Madland⁵, Christian A. Høili⁶, Gunnstein Bakland⁷, Åse Stavland Lexberg⁸, Inger Johanne Widding Hansen⁹, Inger Myrnes Hansen¹⁰, Hilde Haukeland¹¹, Maud-Kristine Aga Ljoså¹², Ellen Moholt¹, Till Uhlig¹, Daniel Solomon¹³, Désirée van der Heijde¹⁴, Tore K. Kvien¹ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Nepal, ³Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁴Revmatismesykehuset, Lillehammer, Norway, ⁵Haukeland University Hospital, Bergen, Norway, ⁶Hospital Østfold HF, Moss, Norway, ⁷University Hospital of North-Norway, Tromsø, Norway, ⁸Drammen Hospital, Vestre Viken HF, Drammen, Norway, ⁹Sørlandet Hospital HF, Kristiansand, Norway, ¹⁰Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹¹Martina Hansens Hospital, Bærum, Norway, ¹²Ålesund Hospital. Møre og Romsdal HF, Ålesund, Norway, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Sustained remission has become an achievable treatment goal for many patients with RA, and drug-free remission has been proposed as a potential extended target…
Abstract Number: 2015 • ACR Convergence 2022
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Naoki Iwamoto², Shoichi Fukui², Fumiko Shomura³, Koichiro Aratake³, Toshiyuki Aramaki⁴, Yukitaka Ueki⁴ and Atsushi Kawakami², ¹Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Ureshino, Japan, ²Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan, ⁴Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan

Background/Purpose: Tofacitinib and baricitinib are the first and second approved JAK inhibitors for rheumatoid arthritis (RA) patients. Although their clinical efficacy has been well established,…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
Abstract Number: 1995 • ACR Convergence 2022
Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
Stephan Kemenes¹, Koray Tascilar², David Simon¹, Sara Bayat³, Gerhard Kroenke², Larissa Valor Mendez², Fabian Hartmann⁴, Louis Schuster⁴, Anna-Maria Liphardt¹, Georg Schett⁵ and Arnd Kleyer², ¹Department of Internal Medicine 3, Rheumatoloy and Immunology, University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁴University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Deterioration of peripheral bone mass and bone biomechanics are well-known consequences of Rheumatoid Arthritis (RA)[1]. CCP-AB pos. RA, in particular, leads to a significant…
Abstract Number: 1998 • ACR Convergence 2022
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
Wendy Walrabenstein¹, Carlijn Wagenaar¹, Marike van der Leeden², Franktien Turkstra¹, Jos Twisk³, Maarten Boers⁴, Henriët van Middendorp⁵, Peter Weijs² and Dirkjan van Schaardenburg², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Epidemiology and Biostatistics, Amsterdam, Netherlands, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁵Leiden University, Leiden, Netherlands
Background/Purpose: Lifestyle factors have been associated with the development and progression of rheumatoid arthritis. Interventions involving whole food plant-based diets (1-3), physical activity (4) or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].